Tirzepatide
Dual GLP-1 / GIP Receptor Agonist
Dual incretin agonist engaging both GLP-1 and GIP receptors. Studied in SURMOUNT-1 (22.5% weight reduction at 72 weeks). Available in 15 mg, 30 mg, and 60 mg vials.
22.5%
Body Wt. Loss
2 (Dual)
Receptors
Once weekly
Dosing
Price
From $134.99
✓ 10% off via PeptidesMuscle
Suggested Protocol
The SURMOUNT-1 titration schedule: 2.5mg weekly for weeks 1–4, then escalate by 2.5mg every four weeks through 5, 7.5, 10, 12.5 and 15mg. The 15mg dose is a maintenance tier, not a starting dose — GI side effects spike sharply if researchers skip titration steps.
Tirzepatide is the first clinically-deployed peptide to simultaneously activate two incretin receptors: GLP-1 (the target of semaglutide) and GIP (glucose-dependent insulinotropic polypeptide). Both incretins are released from intestinal cells after eating; together they coordinate insulin response, appetite signalling, and gastric emptying. By engaging both, tirzepatide produces a larger metabolic effect than any single-receptor agonist before it.
Available Sizes
Specifications
| Product | Tirzepatide |
|---|---|
| Category | Fat Loss / Metabolic |
| Format | Lyophilized powder |
| Price | From $134.99 |
Key Trial Data
| Trial | SURMOUNT-1 Trial (2022) |
|---|---|
| Outcome | 22.5% avg. body weight reduction |
| Duration | 72 weeks |
Reported Endpoints
Dual GLP-1 + GIP activation produces larger weight reduction than any single-agonist incretin in head-to-head trials
SURMOUNT-1 recorded 22.5% mean body-weight loss at 15mg over 72 weeks — a new clinical ceiling
Weekly dosing with ~5-day half-life means one injection covers most of a week
Improves HbA1c, fasting glucose, and triglycerides alongside weight endpoints
Preserves lean mass better than severe caloric restriction in body-composition sub-analyses
SURPASS diabetes trial program showed comparable glycemic control to insulin at lower hypoglycemia risk
Ready to start?
From $134.99
✓ 10% off via PeptidesMuscle
Full Protocol
The SURMOUNT-1 titration schedule: 2.5mg weekly for weeks 1–4, then escalate by 2.5mg every four weeks through 5, 7.5, 10, 12.5 and 15mg. The 15mg dose is a maintenance tier, not a starting dose — GI side effects spike sharply if researchers skip titration steps.
Tirzepatide — FAQs
Further Reading
Similar Fat Loss / Metabolic Compounds
View All
5-Amino-1MQ 50mg x60 Capsules
5-Amino-1MQ in a 60-capsule bottle at 50mg per capsule — the oral-delivery format of the NNMT inhibitor, supplying roughly two months of daily research dosing in a single bottle.
